Real-World COPD study tracks benefits of switching to triple inhaler

NCT ID NCT05915182

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 212 adults with moderate to severe COPD in Greece who were prescribed a triple-combination inhaler (Trixeo Aerosphere). Researchers tracked why patients switched from dual therapy and how their symptoms and quality of life changed over 52 weeks. The goal was to see if the switch helps in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Budesonide, Glycopyrronium bromide, Formoterol fumarate (Trixeo Aerosphere inhaler)
What this could lead to: If successful, this study could show that switching to triple therapy improves daily life for COPD patients in real-world settings, helping doctors make better treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (212 people) and limited to Greece, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE (COPD)

Contacts and locations

Locations

Research Site

Alexandroupoli, 68100, Greece
Research Site

Athens, 11521, Greece
Research Site

Athens, 11527, Greece
Research Site

Athens, 12462, Greece
Research Site

Athens, 17562, Greece
Research Site

Corfu, 49100, Greece
Research Site

Crete, 71409, Greece
Research Site

Crete, 71500, Greece
Research Site

Crete, 73300, Greece
Research Site

Ioannina, 45500, Greece
Research Site

Larissa, 41110, Greece
Research Site

Pátrai, 26332, Greece
Research Site

Pátrai, 26504, Greece
Research Site

Thessaloniki, 56429, Greece
Research Site

Thessaloniki, 57010, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.